Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Scleroderma in children.

Ivan Foeldvari1

  • 1Pediatric Rheumatology Clinic, Allgemeines Krankenhaus Eilbek, Hamburg, Germany. sprechstunde@kinderrheumatologie.de

Current Opinion in Rheumatology
|November 1, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Identifying outcome measures for clinical trials in juvenile idiopathic arthritis associated uveitis for the MIWGUC proposal: a scoping review to create domains from existing outcome measures.

Pediatric rheumatology online journal·2026
Same author

Are we ready to predict progressive disease in juvenile systemic sclerosis?

Journal of scleroderma and related disorders·2026
Same author

What is the treatment pattern of juvenile systemic sclerosis? Results from an international cohort.

Journal of scleroderma and related disorders·2026
Same author

Measuring disease activity in juvenile systemic sclerosis: a multidisciplinary consensus from the Hamburg 2024 symposium.

Expert review of clinical immunology·2026
Same author

Serological biomarkers of JIA-associated uveitis: ANA titers, ANA AC-30 staining pattern and prefoldin 5 antibodies.

Arthritis research & therapy·2026
Same author

What is the best way to plan a 12-month clinical drug trial in JIA associated uveitis?

Expert review of clinical immunology·2026
Same journal

New approaches to the management of cutaneous lupus.

Current opinion in rheumatology·2026
Same journal

"Updates in chronic nonbacterial osteomyelitis: emerging insights across the age spectrum".

Current opinion in rheumatology·2026
Same journal

Difficult-to-treat, complex-to-manage, treatment-refractory spondyloarthritis: semantics or substance?

Current opinion in rheumatology·2026
Same journal

Update on IgA nephropathy: implications for treatment in IgA vasculitis: a guide for rheumatologists.

Current opinion in rheumatology·2026
Same journal

Polyarticular juvenile idiopathic arthritis: insights from genetic studies on disease risk and pathogenesis.

Current opinion in rheumatology·2026
Same journal

Immune dysregulation in children with Down syndrome: clinical implications and emerging therapies.

Current opinion in rheumatology·2026
See all related articles

Juvenile systemic scleroderma (jSSc) research shows progress in classification and assessment methods. However, effective disease-modifying treatments for jSSc and adult systemic scleroderma remain elusive.

Area of Science:

  • Rheumatology
  • Pediatric Rheumatology
  • Immunology

Background:

  • Juvenile systemic scleroderma (jSSc) is a rare childhood autoimmune disease.
  • Limited research exclusively focuses on jSSc, with no major breakthroughs in pathogenesis, classification, or treatment in the review period.
  • Progress in adult systemic scleroderma includes European efforts to establish disease activity indices.

Purpose of the Study:

  • To review recent advancements in juvenile systemic scleroderma (jSSc) and adult systemic scleroderma.
  • To highlight progress in classification systems and assessment methods for jSSc.
  • To discuss current and emerging therapeutic options for systemic scleroderma.

Main Methods:

  • Literature review of recent reports on juvenile and adult systemic scleroderma.

Related Experiment Videos

  • Analysis of proposed classification systems for pediatric populations.
  • Evaluation of European initiatives for adult systemic scleroderma disease activity indices.

    • Main Results:

    • A proposed classification system for jSSc shows progress in defining the pediatric population.
    • European efforts have yielded disease activity indices for adult systemic scleroderma, aiding standardized assessment.
    • Autologous stem cell transplantation trial data published; guidelines proposed for jSSc.
    • Bosentan introduced for pulmonary hypertension in systemic scleroderma offers a therapeutic gain.
    • New prognostic assessment methods are emerging but require validation.

    Conclusions:

    • While classification and assessment tools are improving for jSSc and adult systemic scleroderma, effective disease-modifying treatments are still lacking.
    • Advancements in organ-specific treatments like bosentan for pulmonary hypertension represent significant therapeutic progress.
    • Further validation of new prognostic methods in larger patient cohorts is necessary.